MAPT and Parkinson disease: Of all the functional outcome measures we evaluated in 6-OHDA injected mice and untreated hSYN mice, tau reduction significantly worsened only one: descent latency of 6-OHDA injected mice in the pole test (Fig. 1D), suggesting that the risk of enhancing PD-like alterations by tau reduction may be low.